Home // Events // SAPHNELO® (anifrolumab-fnia): A First-In-Class IFN-1 Signaling Inhibitor, Now With 4-Year Data From a Long-Term Safety and Tolerability Study
SAPHNELO® (anifrolumab-fnia): A First-In-Class IFN-1 Signaling Inhibitor, Now With 4-Year Data From a Long-Term Safety and Tolerability Study
